March 8, 2017 09:38 AM ESTUpdated 11:22 AM

Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics

Arsalan Arif

Founder

Cambridge, MA-based Spero Therapeutics has completed a C round worth $51.7 million, with Google’s venture arm leading the fundraising for a biotech initially seeded at Atlas.

The money will be earmarked for the company’s work on new antibiotics. Investigators have moved into the clinic with SPR741, which used Spero’s platform potentiator tech to puncture the cell membranes of Gram-negative bacteria, opening a new door for Gram-positive antibiotics.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics

Arsalan Arif

Founder

To read Endpoints News become a free subscriber

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Google’s ven­ture arm leads Spero’s $51.7M round for R&D work on a pipeline of new an­tibi­otics

Arsalan Arif

Founder

To read Endpoints News become a free subscriber

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape